Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality

IntroductionTreatment-Resistant Depression (TRD) remains a major challenge in the management of Major Depressive Disorder (MDD). Esketamine, the S-enantiomer of ketamine and a glutamatergic modulator, was approved by the FDA and EMA for TRD in 2019. Beyond its rapid antidepressant effects, esketamin...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Miriam Olivola, Filippo Mazzoni, Barbara Tarantino, Alessandro Guffanti, Matteo Marcatili, Monica Macellaro, Nicolaja Girone, Vassilis Martiadis, Fabiola Raffone, Tiziano Prodi, Natascia Brondino, Giovanni Martinotti, Massimo Clerici, Roberta Anniverno, Bernardo Dell’Osso
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2026-01-01
Schriftenreihe:	Frontiers in Psychiatry
Schlagworte:	cognitive rigidity esketamine major depressive disorder mentalization psychache treatment-resistant depression
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1736114/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!